Cambrex investing $24m in API manufacturing capabilities

(Image: iStock/MeePoohyaphoto)

Cambrex Corporation is investing $24m in a new facility to manufacture highly potent APIs (HPAPIs).

The new facility will be located at the company’s Charles City, Iowa plant. Construction and installation the new equipment is expected to be completed by the first quarter of 2019.

Simon Edwards, VP global sales and marketing, told us 16 additional employees will be added throughout the plant.  

"Along with our existing facilities, we now have a broader range of scale and multi-product capability. Lab space for handling highly potent compounds is also being added," Edwards explained. 

According to the company, the 4,500 sq. ft. production area will operate to an occupational exposure limit (OEL) down to 0.1µg/m3 and have a total reactor capacity of 2,200 gallons. It will include a range of 200, 500, and 1,000-gallon glass and Hastelloy vessels to manufacture batches from 50 to 300kg.

Cambrex will also reconfigure its existing small scale manufacturing area to provide a single high containment building to support early stage development and manufacturing.

The company noted that the expansion is part of a “strategic campaign” to invest in small molecule API development and manufacturing across its facility network.

In 2016, the company opened a $50m, 7,500 sq. ft. multi-purpose manufacturing facility in Charles City. The facility added 70m3 of manufacturing capacity to the site, which is located on 45 acres.

Related News

(Image: iStock/tadamichi)

Cambrex invests $2.4m at former PharmaCore site

Cambrex's Karlskoga facility in Sweden. (Image: Cambrex Corporation)

Cambrex continues to up capacity with more than $200m invested in 5 years

iStock/Rost-9D

Nitto Denko Avecia’s expanded API site to open in Massachusetts, US